Trimel Pharmaceuticals
Trimel Pharmaceuticals develops medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders.
Business Model:
Revenue: $0
Employees: 11-50
Rankings
Industries / Tags:
Detailed Trimel Pharmaceuticals Information
Geographic Data
Address:
City: Mississauga
State: Ontario
Zip:
Country: Canada
Financial Info
Stage:
post ipo equity
Raised Last:
$3M
Raised Total:$70M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Trimel Pharmaceuticals Corporation, a specialty pharmaceutical company, engages in developing medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders. Its product pipeline includes CompleoTRT, a bioadhesive intranasal gel formulation of testosterone, which has completed Phase III clinical study for treating male hypogonadism; Tefina, an intranasal low-dose gel formulation of testosterone, which is in Phase II clinical study for treating female sexual dysfunction; TBS-3, an intranasal gel formulation of dopamine that has completed a preclinical study for the treatment of Parkinson’s disease; and TBS-7 for the prevention and treatment of asthma symptoms. Its products also include TBS-5, which is in the formulation development stage for the long-term treatment of airway inflammation caused by asthma; and TBS-6, which is in the early-stage exploratory development stage for the treatment of allergic rhinitis. The company was founded in 2008 and is headquartered in Mississauga, Canada.
Contact Phone:
Contact Email:
Trimel Pharmaceuticals went public on 5/8/2019 on the OTCQB
Listed Exchange:
OTCQB
IPO Date:
5/8/2019
Ticker Symbol:
ASPCF
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 8/2014 | Post-IPO Equity | $2.1M | 5/2016 | Post-IPO Equity | $2M | 6/2012 | Post-IPO Equity | $12.8M | 3/2019 | Post-IPO Equity | $3.4M | 2/2014 | Post-IPO Equity | 2 | $10.5M |
First Generation Capital West Face Capital First Generation Capital West Face Capital |
3/2013 | Post-IPO Equity | $39M |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
